open access

Vol 93, No 6 (2022)
Review paper
Published online: 2022-05-04
Get Citation

Role of adipokines in ovarian cancer epidemiology and prognosis

Aleksandra Kukla1, Katarzyna Piotrowska2, Marcin Misiek3, Anita M. Chudecka-Glaz1
·
Pubmed: 35766195
·
Ginekol Pol 2022;93(6):496-500.
Affiliations
  1. Klinika Ginekologii Operacyjnej i Onkologii Ginekologicznej Dorosłych i Dziewcząt, Pomeranian Medical University, Szczecin, Poland
  2. Katedra i Zakład Fizjologii, Pomeranian Medical University, Szczecin, Poland
  3. Department of Gynecologic Oncology, Holycross Cancer Center, Kielce, Poland

open access

Vol 93, No 6 (2022)
REVIEW PAPERS Gynecology
Published online: 2022-05-04

Abstract

Ovarian cancer is one of the most serious problems in modern oncological gynecology. The link between obesity (expressed in BMI, WHR, waist circumference, body weight) and ovarian cancer has been poorly studied. Obesity is defined as an excessive accumulation of bodily fat, exceeding its physiological needs and adaptability. Study results suggest a link between specific histological types of ovarian cancer with increased patients’ BMI. Adipose tissue is hormonally active and secretes biologically active proteins called adipokines. Resistin and leptin may show proliferative and anti-apoptotic effects. There is currently increasing attention to adipokine levels in ovarian cancer research. The influence of adiponectin on the secretion of angiogenic factors by ovarian cancer cells has been shown. It has been proven that leptin is associated with a worse prognosis for patients treated with platinum compounds combined with paclitaxel/docetaxel. The relation has been observed between the level of resistin and the growth of neoplastic cells, their spread and the resistance to chemotherapy. The level of AdipoR1 may be independent prognostic factor in the case of epithelial ovarian cancer. The role of adipokine in the neoplasm development requires further investigation, in the view of fact that results of current research are still inconclusive. Considering increasing number of people suffering from obesity as well as the current analysis results, it is necessary to extend experimentation on the influence of obesity on the development and prognosis of ovarian cancer.

Abstract

Ovarian cancer is one of the most serious problems in modern oncological gynecology. The link between obesity (expressed in BMI, WHR, waist circumference, body weight) and ovarian cancer has been poorly studied. Obesity is defined as an excessive accumulation of bodily fat, exceeding its physiological needs and adaptability. Study results suggest a link between specific histological types of ovarian cancer with increased patients’ BMI. Adipose tissue is hormonally active and secretes biologically active proteins called adipokines. Resistin and leptin may show proliferative and anti-apoptotic effects. There is currently increasing attention to adipokine levels in ovarian cancer research. The influence of adiponectin on the secretion of angiogenic factors by ovarian cancer cells has been shown. It has been proven that leptin is associated with a worse prognosis for patients treated with platinum compounds combined with paclitaxel/docetaxel. The relation has been observed between the level of resistin and the growth of neoplastic cells, their spread and the resistance to chemotherapy. The level of AdipoR1 may be independent prognostic factor in the case of epithelial ovarian cancer. The role of adipokine in the neoplasm development requires further investigation, in the view of fact that results of current research are still inconclusive. Considering increasing number of people suffering from obesity as well as the current analysis results, it is necessary to extend experimentation on the influence of obesity on the development and prognosis of ovarian cancer.

Get Citation

Keywords

ovarian cancer; adiponectin; leptin; resistin; visfatin; adipokines

About this article
Title

Role of adipokines in ovarian cancer epidemiology and prognosis

Journal

Ginekologia Polska

Issue

Vol 93, No 6 (2022)

Article type

Review paper

Pages

496-500

Published online

2022-05-04

Page views

4981

Article views/downloads

969

DOI

10.5603/GP.a2022.0035

Pubmed

35766195

Bibliographic record

Ginekol Pol 2022;93(6):496-500.

Keywords

ovarian cancer
adiponectin
leptin
resistin
visfatin
adipokines

Authors

Aleksandra Kukla
Katarzyna Piotrowska
Marcin Misiek
Anita M. Chudecka-Glaz

References (33)
  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
  2. American Cancer Society. Cancer Facts & Figures 2022. Ga: American Cancer Society; Atlanta, 2022.
  3. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy. http://onkologia.org.pl/raporty.
  4. Kordek R, Jassem J, Jeziorski A. ONKOLOGIA. Podręcznik dla studentów i lekarzy, wyd. 4. Via Medica, Gdańsk 2013.
  5. Kujawa KA, Lisowska K. Ovarian cancer – from biology to clinic. Postępy Higieny i Medycyny Doświadczalnej. 2015; 69: 1275–1290.
  6. Khabaz MN, Qureshi IA, Al-Maghrabi JA. GLUT 1 expression is a supportive mean in predicting prognosis and survival estimates of endometrial carcinoma. Ginekol Pol. 2019; 90(10): 582–588.
  7. World Health Organization: Obesity: Preventing and Managing the Global Epidemic (Who Technical Report Series, 2000).
  8. Heymsfield SB, Wadden TA, Heymsfield SB, et al. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017; 376(3): 254–266.
  9. Timper K, Brüning JC. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. Dis Model Mech. 2017; 10(6): 679–689.
  10. Gogga* P, Karbowska* J, Meissner W, et al. Rola leptyny w regulacji metabolizmu lipidów i węglowodanów. Postępy Higieny i Medycyny Doświadczalnej. 2011; 65: 255–262.
  11. Dimou NL, Papadimitriou N, Mariosa D, et al. CCFR, Endometrial Cancer Association Consortium. Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study. Int J Cancer. 2021; 148(7): 1625–1636.
  12. Beyazit F, Hiz MM, Turkon H, et al. Serum spexin, adiponectin and leptin levels in polycystic ovarian syndrome in association with FTO gene polymorphism. Ginekol Pol. 2021; 92(10): 682–688.
  13. Eguchi T, Yasuhide N, Tetsutaro Y, et al. Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Science. 2010; 101(5): 1286–1291.
  14. Kumari B, Yadav UCS. Adipokine Visfatin's Role in Pathogenesis of Diabesity and Related Metabolic Derangements. Curr Mol Med. 2018; 18(2): 116–125.
  15. Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014; 384(9945): 755–765.
  16. Himbert C, Delphan M, Scherer D, et al. Signals from the Adipose Microenvironment and the Obesity–Cancer Link—A Systematic Review. Cancer Prevention Research. 2017; 10(9): 494–506.
  17. Parida S, Siddharth S, Sharma D. Adiponectin, Obesity, and Cancer: Clash of the Bigwigs in Health and Disease. Int J Mol Sci. 2019; 20(10).
  18. Tworoger SS, Huang T. Obesity and Ovarian Cancer. Recent Results Cancer Res. 2016; 208: 155–176.
  19. Mrochem J, Sodowski K, Deja R, et al. Ocena mozliwości wczesnej diagnostyki raka jajnika na podstawie oznaczeń wybranych białek surowicy [Evaluation of selected serum protein markers as early detectors of ovarian cancer]. Ginekol Pol. 2008; 79(4): 271–5.
  20. Ray A, Fornsaglio J, Dogan S, et al. Gynaecological cancers and leptin: A focus on the endometrium and ovary. Facts Views Vis Obgyn. 2018; 10: 5–18.
  21. Himbert C, Delphan M, Scherer D, et al. Signals from the Adipose Microenvironment and the Obesity-Cancer Link-A Systematic Review. Cancer Prev Res (Phila). 2017; 10(9): 494–506.
  22. Achkar I, Bhat A, Zafar M, et al. Oncogenic role of dysregulated leptin signaling in the pathogenesis of ovarian cancer. Translational Medicine Communications. 2019; 4(1).
  23. Ouh YT, Cho HW, Lee JK, et al. CXC chemokine ligand 1 mediates adiponectin-induced angiogenesis in ovarian cancer. Tumour Biol. 2019; 42(4): 1010428319842699.
  24. Jin JH, Kim HJ, Kim CY, et al. Association of plasma adiponectin and leptin levels with the development and progression of ovarian cancer. Obstet Gynecol Sci. 2016; 59(4): 279–285.
  25. Ramzan AA, Bitler BG, Hicks D, et al. Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells. Mol Cell Biochem. 2019; 461(1-2): 37–46.
  26. Hoffmann M, Gogola J, Ptak A. Adiponectin Reverses the Proliferative Effects of Estradiol and IGF-1 in Human Epithelial Ovarian Cancer Cells by Downregulating the Expression of Their Receptors. Horm Cancer. 2018; 9(3): 166–174.
  27. Gu F, Zhang H, Yao L, et al. Leptin contributes to the taxol chemoresistance in epithelial ovarian cancer. Oncol Lett. 2019; 18(1): 561–570.
  28. Ghasemi A, Saeidi J, Mohtashami M, et al. Estrogen-independent role of ERα in ovarian cancer progression induced by leptin/Ob-Rb axis. Mol Cell Biochem. 2019; 458(1-2): 207–217.
  29. Crean-Tate KK, Reizes O. Leptin Regulation of Cancer Stem Cells in Breast and Gynecologic Cancer. Endocrinology. 2018; 159(8): 3069–3080.
  30. Chin YT, Wang LM, Hsieh MT, et al. Leptin OB3 peptide suppresses leptin-induced signaling and progression in ovarian cancer cells. J Biomed Sci. 2017; 24(1): 51.
  31. Wei X, Liu Yi, Gong C, et al. Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis. Anticancer Agents Med Chem. 2017; 17(8): 1093–1101.
  32. Ghasemi A, Hashemy SI, Aghaei M, et al. RhoA/ROCK pathway mediates leptin-induced uPA expression to promote cell invasion in ovarian cancer cells. Cell Signal. 2017; 32: 104–114.
  33. Qiu L, Zhang GF, Yu L, et al. Novel oncogenic and chemoresistance-inducing functions of resistin in ovarian cancer cells require miRNAs-mediated induction of epithelial-to-mesenchymal transition. Sci Rep. 2018; 8(1): 12522.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl